DK0698012T3 - - Google Patents

Info

Publication number
DK0698012T3
DK0698012T3 DK94916021.2T DK94916021T DK0698012T3 DK 0698012 T3 DK0698012 T3 DK 0698012T3 DK 94916021 T DK94916021 T DK 94916021T DK 0698012 T3 DK0698012 T3 DK 0698012T3
Authority
DK
Denmark
Prior art keywords
novel
alkyl
deoxygalactonojirimycin
useful
carbon atoms
Prior art date
Application number
DK94916021.2T
Other languages
Danish (da)
English (en)
Inventor
Frances M Platt
Gabrielle R Neises
Raymond A Dwek
Terry D Butters
Original Assignee
Monsanto Co
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/061,645 external-priority patent/US5399567A/en
Application filed by Monsanto Co, Searle & Co filed Critical Monsanto Co
Application granted granted Critical
Publication of DK0698012T3 publication Critical patent/DK0698012T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/131Amines acyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/46Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
DK94916021.2T 1993-05-13 1994-05-11 DK0698012T3 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/061,645 US5399567A (en) 1993-05-13 1993-05-13 Method of treating cholera
US08/102,654 US6291657B1 (en) 1993-05-13 1993-08-05 Deoxygalactonojirimycin derivatives

Publications (1)

Publication Number Publication Date
DK0698012T3 true DK0698012T3 (fr) 1997-02-17

Family

ID=26741316

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94916021.2T DK0698012T3 (fr) 1993-05-13 1994-05-11

Country Status (11)

Country Link
US (3) US6291657B1 (fr)
EP (1) EP0698012B1 (fr)
JP (1) JP3636363B2 (fr)
AT (1) ATE148456T1 (fr)
AU (1) AU6783294A (fr)
CA (1) CA2159988C (fr)
DE (1) DE69401658T2 (fr)
DK (1) DK0698012T3 (fr)
ES (1) ES2097653T3 (fr)
GR (1) GR3022554T3 (fr)
WO (1) WO1994026714A1 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5798366A (en) * 1993-05-13 1998-08-25 Monsanto Company Method for treatment of CNS-involved lysosomal storage diseases
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
WO2000029556A2 (fr) * 1998-11-17 2000-05-25 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Identification des glycosphingolipides qui favorisent la penetration du vih-1 dans les cellules
US6610703B1 (en) 1998-12-10 2003-08-26 G.D. Searle & Co. Method for treatment of glycolipid storage diseases
GB0100889D0 (en) 2001-01-12 2001-02-21 Oxford Glycosciences Uk Ltd Compounds
GB9909066D0 (en) * 1999-04-20 1999-06-16 Oxford Glycosciences Uk Ltd Therapies
US20050032841A1 (en) * 1999-04-20 2005-02-10 Steven Walkley Therapeutic compositions and methods of treating glycolipid storage related disorders
CA2378776A1 (fr) 1999-07-26 2001-02-01 G.D. Searle & Co. Utilisation de derives n-alkyle de deoxynojirimycine a chaine longue et d'enzyme glucocerebro-sidase pour fabriquer un medicament permettant de traiter des maladies provoquees parle stockage de glycolipides
US7256005B2 (en) 1999-08-10 2007-08-14 The Chancellor, Masters And Scholars Of The University Of Oxford Methods for identifying iminosugar derivatives that inhibit HCV p7 ion channel activity
AU1840101A (en) * 1999-08-10 2001-03-05 Chancellor, Masters And Scholars Of The University Of Oxford, The Long chain n-alkyl compounds and oxo-derivatives thereof
AU2003246942B2 (en) 2002-07-17 2009-06-25 Idorsia Pharmaceuticals Ltd Piperidinetriol derivatives as inhibitors of glycosylceramide synthase
AU2003248960B2 (en) 2002-07-17 2009-06-25 Idorsia Pharmaceuticals Ltd Piperidinetriol derivatives as inhibitors of glycosylceramidsynthase
GB0229476D0 (en) * 2002-12-17 2003-01-22 Oxford Glycosciences Uk Ltd Novel process
US20040180419A1 (en) 2003-01-31 2004-09-16 Mount Sinai School Of Medicine Of New York University Combination therapy for treating protein deficiency disorders
GB0313677D0 (en) 2003-06-13 2003-07-16 Oxford Glycosciences Uk Ltd Novel compound
GB0313678D0 (en) 2003-06-13 2003-07-16 Oxford Glycosciences Uk Ltd Novel compounds
AU2004289327A1 (en) * 2003-11-12 2005-05-26 Amicus Therapeutics Inc. Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat Gaucher disease
US20050256168A1 (en) * 2004-04-28 2005-11-17 Block Timothy M Compositions for oral administration for the treatment of interferon-responsive disorders
US20090111812A1 (en) * 2004-06-14 2009-04-30 Musc Foundation For Research Development Methods for treating inflammatory disorders
US9181184B2 (en) 2005-05-17 2015-11-10 Amicus Therapeutics, Inc. Method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
GB0614947D0 (en) * 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy
WO2008088581A2 (fr) * 2006-08-02 2008-07-24 United Therapeutics Corporation Traitement liposomal d'infections virales
CN102046151A (zh) * 2008-03-26 2011-05-04 牛津大学 靶向内质网的脂质体
EP2411526A4 (fr) * 2009-03-27 2012-09-19 Zacharon Pharmaceuticals Inc Modulateurs de la biosynthèse des gangliosides
EP2410989A2 (fr) * 2009-03-27 2012-02-01 The Chancellor, Masters and Scholars of the University of Oxford Liposomes réducteurs du taux de cholestérol
LT2655388T (lt) 2010-12-23 2016-11-10 Alectos Therapeutics Inc. Selektyvieji glikozidazės inhibitoriai ir jų panaudojimas
WO2012129651A1 (fr) 2011-03-31 2012-10-04 Alectos Therapeutics Inc. Inhibiteurs sélectifs de glycosidases et leurs utilisations
EP2726492B1 (fr) 2011-06-27 2017-11-01 Alectos Therapeutics Inc. Inhibiteurs de glycosidases sélectifs et leurs utilisations
WO2014032188A1 (fr) 2012-08-31 2014-03-06 Alectos Therapeutics Inc. Inhibiteurs des glycosidases et leurs utilisations
US9522883B2 (en) * 2012-08-31 2016-12-20 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
EP2890676B1 (fr) 2012-08-31 2018-12-05 Alectos Therapeutics Inc. Inhibiteurs de glycosidases et leurs utilisations
AU2013337570B2 (en) 2012-10-31 2018-01-18 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
EP2943200B9 (fr) 2013-01-09 2020-07-22 Amicus Therapeutics, Inc. Compositions de dnj parentérales stables
EP3630725A1 (fr) * 2017-06-01 2020-04-08 Idorsia Pharmaceuticals Ltd Forme cristalline de n-butyldéoxygalactonojirimycine
WO2021061701A1 (fr) 2019-09-25 2021-04-01 Teva Pharmaceuticals International Gmbh Formes à l'état solide de sels de lucérastat et leur procédé de préparation
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same
WO2022132992A1 (fr) 2020-12-16 2022-06-23 Amicus Therapeutics, Inc. Lots hautement purifiés de composés de 1-désoxygalactonojirimycine de qualité pharmaceutique

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1555654A (en) 1977-06-25 1979-11-14 Exxon Research Engineering Co Agricultural burner apparatus
US4065562A (en) 1975-12-29 1977-12-27 Nippon Shinyaku Co., Ltd. Method and composition for reducing blood glucose levels
NO154918C (no) 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
GB2020278B (en) 1978-05-03 1983-02-23 Nippon Shinyaku Co Ltd Moranoline dervitives
WO1987003903A1 (fr) 1985-12-23 1987-07-02 Fred Hutchinson Cancer Research Center Regulation de la replication, de l'infection et de la pathogenese retrovirales
US4849430A (en) 1988-03-09 1989-07-18 Monsanto Company Method of inhibiting virus
US5011829A (en) * 1989-06-02 1991-04-30 G. D. Searle & Co. Pharmaceutical composition and method of inhibiting virus
US5030638A (en) 1990-02-26 1991-07-09 G. D. Searle & Co. Method of antiviral enhancement
CA2086413A1 (fr) 1990-06-29 1991-12-30 Yohji Ezure Derives piperidine
US5128347A (en) * 1990-10-18 1992-07-07 Monsanto Company Glycosidase inhibiting 1,4-dideoxy-4-fluoronojirimycin

Also Published As

Publication number Publication date
DE69401658D1 (de) 1997-03-13
CA2159988C (fr) 2007-01-09
WO1994026714A1 (fr) 1994-11-24
US6291657B1 (en) 2001-09-18
US5580884A (en) 1996-12-03
ATE148456T1 (de) 1997-02-15
DE69401658T2 (de) 1997-06-12
ES2097653T3 (es) 1997-04-01
AU6783294A (en) 1994-12-12
CA2159988A1 (fr) 1994-11-24
JP3636363B2 (ja) 2005-04-06
US5786368A (en) 1998-07-28
GR3022554T3 (en) 1997-05-31
JPH08510244A (ja) 1996-10-29
EP0698012B1 (fr) 1997-01-29
EP0698012A1 (fr) 1996-02-28

Similar Documents

Publication Publication Date Title
DK0698012T3 (fr)
ZA955466B (en) Stereochemical wortmannin derivatives
ZA976705B (en) Process for the synthesis of protected esters of (S)-3,4-dihydroxybutric acid.
GB2301106B (en) Synergistic stabilizer mixture
HU9302335D0 (en) 9-|(substituted glycyl)-amido¨-6-desmethyl-6-desoxy-tetracyclines
EP0477531A3 (en) Process for inhibiting and destroying peroxides in dialkyl ethers
HK1019878A1 (en) Total synthesis of antitumor acylfulvenes.
HU9503370D0 (en) N-alkylthio polyamine derivatives as radioprotective agents
HU9500559D0 (en) New mercapto-acetamide tricyclic derivatives as enkephalinase-inhibitors
ZA858169B (en) New adamantanamine derivatives,processes for their preparation and drugs in which they are present
MX9801190A (es) Inhibidores de prolil endopeptidasa.
UA66866C2 (uk) Синтез морфолінових похідних
AP9400632A0 (en) Ether derivatives.
IL128951A0 (en) Tricyclic compounds useful for inhibition of farnesyl protein transferase
GR1002598B (el) Παραγωγα επι-επιβατιδινης.
AU5176093A (en) Oleaginous compositions
HU906010D0 (en) New substituted alkyl-piperidine derivatives
ZA9811380B (fr)
YU71400A (sh) Poboljšani postupak za pripremanje farmaceutski dragocenih derivata norbenzomorfana
ES2023760A6 (es) Procedimiento para la preparacion de derivados benzotiazinicos.
MX9801130A (es) Tiamacrolidos.
PL342992A1 (en) New compounds
AU6663596A (en) One pot synthesis of 2-oxazolidinone derivatives
GR3029453T3 (en) NOVEL PROCESSES AND INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF PLATELET CLYCOPROTEIN IIb/IIIa INHIBITORS
TW333554B (en) Benzidine derivative and electrophotosensitive material using the same